Eli Lilly Retatrutide Phase 3: 28.3% Weight Loss Pushes Obesity Into a Portfolio War | Witfire Elite View Witfire Elite Pharma News Investments Stock Market Breaking Analysis 28.3 Pharma Market Case Study · Witfire Elite View Eli Lilly Retatrutide Phase 3 Results A 28.3% average weight loss at 80 weeks is the headline. But the […]
Eli Lilly Retatrutide Phase 3 Results at ADA 2026 Read More »
The Pharma Tariff War: How US Drug Pricing Pressure Is Forcing Big Pharma to Rewrite Global Strategy | Witfire Elite View Witfire Elite Pharma Markets Case Studies Strategy Long Read Pharma Market Case Study Witfire Elite View The Pharma Tariff War How US Drug Pricing Pressure Is Forcing Big Pharma to Rewrite Global Strategy A
The US-Israel-Iran war is affecting pharma stocks, drug supply chains, logistics costs, cold-chain movement, and investor sentiment as oil and freight costs rise. The US-Israel-Iran war is now becoming more than a geopolitical headline for the pharmaceutical industry. For pharma CEOs, investors, exporters, logistics companies, and healthcare suppliers, the conflict is creating a new layer
The stock market is now looking at the US-Israel-Iran conflict through a sharper pharma lens. This is no longer only a war story, an oil story, or a Wall Street volatility story. For pharmaceutical companies, this conflict has become a supply-chain test, a margin test, and a leadership test. Global markets turned cautious as fresh
